Skip to content

Oric Pharmaceuticals

US · ORIC #3089 by market cap Listed 2020
7.36 -0.34 -4.42%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Company notice
    Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.
    SEC · 2025/10/4
  • Rating change
    H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $27
    Market Newswire · 2026/8/10
  • Guggenheim Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $18
    Market Newswire · 2026/10/22
  • Rating change
    J.P. Morgan Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $26
    Market Newswire · 2026/10/14
  • Company notice
    Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.
    SEC · 2026/1/7
  • Company notice
    Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Hoerter Steven L.
    SEC · 2026/1/7
  • Rating change
    Piper Sandler Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $22
    Market Newswire · 2026/6/29
  • H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $27
    Market Newswire · 2026/10/27
  • Stifel Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $18
    Market Newswire · 2026/10/30
  • Rating change
    HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27
    Benzinga · 2026/8/10
  • Company notice
    Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.
    SEC · 2026/10/3
  • Rating change
    Stifel Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $18
    Market Newswire · 2026/10/26
  • Rating change
    BTIG Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $26
    Market Newswire · 2026/10/26
  • Insiders Sold ORIC Pharmaceuticals At US$12.02, Meanwhile Stock Sits Near US$7.86
    Simply Wall St · 2026/11/14
  • Rating change
    J.P. Morgan Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $23
    Market Newswire · 2026/8/7
  • Rating change
    BTIG Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $26
    Market Newswire · 2026/9/23
  • A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $25 to $27
    Market Newswire · 2026/10/28
  • Company notice
    Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.
    SEC · 2026/1/21
  • Rating change
    A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $14 to $25
    Market Newswire · 2026/8/5
  • Rating change
    JonesTrading Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25
    Market Newswire · 2026/10/23
  • Rating change
    H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25
    Market Newswire · 2026/6/24
  • Rating change
    Wells Fargo Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25
    Market Newswire · 2026/6/11
  • Rating change
    Goldman Sachs Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $15
    Market Newswire · 2026/6/3
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (ARDT), Tactile Systems Technology (TCMD) and Oric Pharmaceuticals (ORIC)
    TipRanks · 2026/6/3
  • Rating change
    HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target
    Benzinga · 2026/6/8

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Oric Pharmaceuticals discussion 0 comments

Add a comment